296 related articles for article (PubMed ID: 30209442)
21. Epithelial Mesenchymal Transition in Aggressive Lung Cancers.
Mittal V
Adv Exp Med Biol; 2016; 890():37-56. PubMed ID: 26703798
[TBL] [Abstract][Full Text] [Related]
22. Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.
Liao BC; Lin CC; Lee JH; Yang JC
Lung Cancer; 2017 Aug; 110():7-13. PubMed ID: 28676222
[TBL] [Abstract][Full Text] [Related]
23. Advanced non-Small cell lung cancer patients at the extremes of age in the era of epidermal growth factor receptor tyrosine kinase inhibitors.
Chen YM; Lai CH; Rau KM; Huang CH; Chang HC; Chao TY; Tseng CC; Fang WF; Chen YC; Chung YH; Wang YH; Su MC; Huang KT; Liu SF; Chen HC; Chang YC; Chang YP; Wang CC; Lin MC
Lung Cancer; 2016 Aug; 98():99-105. PubMed ID: 27393514
[TBL] [Abstract][Full Text] [Related]
24. Extracellular vesicles shed from gefitinib-resistant nonsmall cell lung cancer regulate the tumor microenvironment.
Choi DY; You S; Jung JH; Lee JC; Rho JK; Lee KY; Freeman MR; Kim KP; Kim J
Proteomics; 2014 Aug; 14(16):1845-56. PubMed ID: 24946052
[TBL] [Abstract][Full Text] [Related]
25. Targeted Therapy and Immune Therapy for Small Cell Lung Cancer.
Gadgeel SM
Curr Treat Options Oncol; 2018 Sep; 19(11):53. PubMed ID: 30203184
[TBL] [Abstract][Full Text] [Related]
26. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
27. A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization.
Hensing T; Chawla A; Batra R; Salgia R
Adv Exp Med Biol; 2014; 799():85-117. PubMed ID: 24292963
[TBL] [Abstract][Full Text] [Related]
28. Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy.
Biello F; Burrafato G; Rijavec E; Genova C; Barletta G; Truini A; Coco S; Bello MG; Alama A; Boccardo F; Grossi F
Anticancer Agents Med Chem; 2016; 16(9):1142-54. PubMed ID: 26845137
[TBL] [Abstract][Full Text] [Related]
29. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
Marquez-Medina D; Popat S
Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
[TBL] [Abstract][Full Text] [Related]
30. Evolving Cancer Classification in the Era of Personalized Medicine: A Primer for Radiologists.
O'Neill AC; Jagannathan JP; Ramaiya NH
Korean J Radiol; 2017; 18(1):6-17. PubMed ID: 28096714
[TBL] [Abstract][Full Text] [Related]
31. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
32. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F
Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058
[TBL] [Abstract][Full Text] [Related]
33. Advanced EGFR mutation-positive non-small-cell lung cancer: case report, literature review, and treatment recommendations.
Kuykendall A; Chiappori A
Cancer Control; 2014 Jan; 21(1):67-73. PubMed ID: 24357744
[TBL] [Abstract][Full Text] [Related]
34. Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer.
Galvani E; Alfieri R; Giovannetti E; Cavazzoni A; La Monica S; Galetti M; Fumarola C; Bonelli M; Mor M; Tiseo M; Peters GJ; Petronini PG; Ardizzoni A
Curr Pharm Des; 2013; 19(5):818-32. PubMed ID: 22973953
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR.
Li J; Deng H; Hu M; Fang Y; Vaughn A; Cai X; Xu L; Wan W; Li Z; Chen S; Yang X; Wu S; Xiao J
Oncotarget; 2015 Mar; 6(9):6749-61. PubMed ID: 25730907
[TBL] [Abstract][Full Text] [Related]
36. Targeted therapies for small cell lung cancer: Where do we stand?
Arcaro A
Crit Rev Oncol Hematol; 2015 Aug; 95(2):154-64. PubMed ID: 25800975
[TBL] [Abstract][Full Text] [Related]
37. Targeting apoptosis by 1,2-diazole through regulation of EGFR, Bcl-2 and CDK-2 mediated signaling pathway in human non-small cell lung carcinoma A549 cells.
Vinod Prabhu V; Elangovan P; Niranjali Devaraj S; Sakthivel KM
Gene; 2018 Dec; 679():352-359. PubMed ID: 30218747
[TBL] [Abstract][Full Text] [Related]
38. [Not Available].
Evers G; Mohr M; Kerkhoff A; Lenz G; Wiewrodt R; Schmidt LH
Dtsch Med Wochenschr; 2017 Oct; 142(20):1531-1534. PubMed ID: 29017211
[TBL] [Abstract][Full Text] [Related]
39. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH; Soo RA
Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
[TBL] [Abstract][Full Text] [Related]
40. Personalised medicine for nonsmall cell lung cancer.
Mascaux C; Tomasini P; Greillier L; Barlesi F
Eur Respir Rev; 2017 Dec; 26(146):. PubMed ID: 29141962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
